HOME
PRODUCTS
COMPANY
CONTACT
FAQ
Research
Dictionary
Pharma
Sign Up
FREE
or
Login
Username:
Password:
Remember login
Login
Send password reminder...
indecainide
structure given in first source; RN given refers to parent cpd
Also Known As:
9-(3-((1-methylethyl)amino)propyl)-9H-fluorene-9-carboxamide; indecainide hydrochloride
Networked:
15
relevant articles (
0
outcomes,
2
trials/studies)
Drug Context: Research Results
Organic Chemicals: 133
Hydrocarbons: 1713
Cyclic Hydrocarbons: 97
Aromatic Hydrocarbons: 291
Polycyclic Aromatic Hydrocarbons: 2020
Fluorenes: 7
indecainide: 15
Polycyclic Compounds: 6
Polycyclic Aromatic Hydrocarbons: 2020
Fluorenes: 7
indecainide: 15
Related Diseases
1.
Cardiac Arrhythmias (Arrythmia)
06/01/1987 - "
An oral short-term in-hospital trial in 20 patients (8 patients entered directly from the intravenous short-term trial) was conducted using a single-blind placebo dose titration protocol in which 50 mg of indecainide every 8 hours was increased at 3-day intervals to 75 mg, and then 100 mg every 8 hours depending on the observed change in ventricular arrhythmia frequency by Holter monitoring.
"
04/01/1988 - "
Indecainide is an effective antiarrhythmic agent in a small number of highly selected patients with serious ventricular arrhythmia, but potentially serious side effects limit its usefulness.
"
02/01/1985 - "
Indecainide is a new (investigational) drug for treating cardiac arrhythmias.
"
07/01/1990 - "
A total of 8 patients had serious toxicity during the intravenous phase; 6 receiving indecainide experienced increased left ventricular dysfunction or worsening arrhythmia (sustained VT, arrhythmic death) while 2 receiving procainamide developed serious hypotension.
"
2.
Body Weight (Weight, Body)
10/01/1987 - "
Mean body weight gain was slightly decreased throughout the study in mice receiving 0.02 or 0.04%, while mice receiving 0.08% indecainide had moderately decreased body weight gain.
"
3.
Ventricular Tachycardia
04/01/1988 - "
Among seven patients with nonsustained ventricular tachycardia, five had 100% elimination of these events with indecainide and all had greater than or equal to 90% reduction in these events.
"
04/01/1988 - "
Noninvasive evaluation of indecainide for serious ventricular tachyarrhythmia.
"
06/01/1987 - "
Indecainide was well tolerated, but 2 patients died of ventricular tachyarrhythmias while receiving the drug.
"
06/01/1987 - "
Antiarrhythmic effects of oral indecainide in patients with ventricular tachyarrhythmias.
"
01/01/1987 - "
Twelve of 15 patients were still inducible for ventricular tachycardia on indecainide.
"
4.
Ventricular Premature Complexes (Premature Ventricular Contraction)
07/01/1990 - "
In those tolerating indecainide, long-term suppression of ventricular premature complexes (VPCs) and of runs of VT was more consistent than with procainamide.
"
09/01/1987 - "
Cardiac patients with greater than or equal to 30 ventricular premature complexes per hour hour received indecainide, 50 mg, or quinidine, 200 mg every 6 hours, and the doses were increased until more than 80% suppression was noted, adverse effects occurred or a maximal dose of 100 mg of indecainide or 400 mg of quinidine given every 6 hours.
"
11/01/1990 - "
Indecainide, a new antiarrhythmic agent classified as type Ic was evaluated in 11 patients with heart disease who had greater than or equal to 30 ventricular premature complexes/hour, moderate-to-marked left ventricular dysfunction, and mean ejection fraction 34% +/- 8%.
"
5.
Left Ventricular Dysfunction
11/01/1990 - "
Effect of indecainide in patients with left ventricular dysfunction.
"
07/01/1990 - "
Indecainide has a poor risk-benefit ratio in patients similar to the current population, who have potentially lethal ventricular arrhythmias and severe left ventricular dysfunction.
"
07/01/1990 - "
While indecainide was a potent suppressor of spontaneous VPCs and VT, patients with significant left ventricular dysfunction could not tolerate it.
"
10/01/1985 - "
The electrophysiologic effects of indecainide, a new class IC antiarrhythmic agent, were assessed in 10 patients with left ventricular dysfunction and inducible sustained ventricular tachycardia.
"
11/01/1990 - "
Indecainide, a new antiarrhythmic agent classified as type Ic was evaluated in 11 patients with heart disease who had greater than or equal to 30 ventricular premature complexes/hour, moderate-to-marked left ventricular dysfunction, and mean ejection fraction 34% +/- 8%.
"
Related Drugs and Biologics
1.
Procainamide (Procan)
2.
Tocainide (Tonocard)
3.
Investigational Drugs
4.
Quinidine (Chinidin)
5.
Mexiletine (Mexitil)
6.
Lidocaine (Xylocaine)
7.
Calcium
8.
Aprindine
9.
Anti-Arrhythmia Agents
10.
Ajmaline (Wolfina)
Related Therapies and Procedures
1.
Therapeutics
2.
Drug Therapy (Chemotherapy)